The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
Abstract
Five parkinsonian patients were transplanted bilaterally into the putamen and caudate nucleus with human embryonic mesencephalic tissue from between seven and nine donors. To increase graft survival, the lipid peroxidation inhibitor tirilazad mesylate was administered to the tissue before implantation and intravenously to the patients for 3 days thereafter. During the second postoperative year, the mean daily L-dopa dose was reduced by 54% and the UPDRS (Unified Parkinson's Disease Rating Scale) motor score in 'off' phase was reduced by a mean of 40%. At 10-23 months after grafting, PET showed a mean 61% increase of 6-L-[(18)F]fluorodopa uptake in the putamen, and 24% increase in the caudate nucleus, compared with preoperative values. No obvious differences in the pattern of motor recovery were observed between these and other previously studied cases with putamen grafts alone. The amount of mesencephalic tissue implanted in each putamen and caudate nucleus was 42 and 50% lower, respectively, compared with previously transplanted patients from our centre. Despite this reduction in grafted tissue, the magnitudes of symptomatic relief and graft survival were very similar. These findings suggest that tirilazad mesylate may improve survival of grafted dopamine neurons in patients, which is in agreement with observations in experimental animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Grafts of Fetal Dopamine Neurons Survive and Improve Motor Function in Parkinson's Disease
Lindvall, O., Brundin, P., Widner, H., Rehncrona, S., Gustavii, B., Frackowiak, R., Leenders, K. L., Sawle, G., Rothwell, J. C., Marsden, C. D., et al. (1990) · Science · doi:10.1126/science.2105529 · Cited by 1,207
Self-citationThe behavioural and motor consequences of focal lesions of the basal ganglia in man
Bhatia, K. P., & Marsden, C. D. (1994) · Brain · doi:10.1093/brain/117.4.859 · Cited by 1,073
Core assessment program for intracerebral transplantations (CAPIT)
Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., & Watts, R. (1992) · Movement Disorders · doi:10.1002/mds.870070103 · Cited by 1,008
Kordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J. G., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Smith, D. A., Nauert, G. M., Perl, D. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321702 · Cited by 860
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
Piccini, P., Brooks, D. J., Björklund, A., Gunn, R. N., Grasby, P. M., Rimoldi, O., Brundin, P., Hagell, P., Rehncrona, S., Widner, H., et al. (1999) · Nature Neuroscience · doi:10.1038/16060 · Cited by 700
Self-citationLindvall, O. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520420033021 · Cited by 535
Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats
Studer, L., Tabar, V., & McKay, R. (1998) · Nature Neuroscience · doi:10.1038/1105 · Cited by 529
Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., Björklund, A., Lindvall, O., & Langston, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211263272203 · Cited by 488
Self-citationLindvall, O., Sawle, G., Widner, H., Rothwell, J. C., Björklund, A., Brooks, D., Brundin, P., Frackowiak, R., Marsden, C. D., Odin, P., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410350208 · Cited by 451
Self-citation
Cited by
A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Doi, D., Samata, B., Katsukawa, M., Kikuchi, T., Morizane, A., Ono, Y., Sekiguchi, K., Nakagawa, M., Parmar, M., & Takahashi, J. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.01.013 · Cited by 431
Neural transplantation for the treatment of Parkinson's disease
Björklund, A., Dunnett, S. B., Brundin, P., Stoessl, A. J., Freed, C. R., Breeze, R. E., Levivier, M., Peschanski, M., Studer, L., & Barker, R. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00442-3 · Cited by 356
Self-citationCellular imaging in drug discovery
Lang, P., Yeow, K., Nichols, A., & Scheer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2008 · Cited by 351
Cell therapy in Parkinson’s disease
Lindvall, O., & Björklund, A. (2004) · NeuroRX · doi:10.1602/neurorx.1.4.382 · Cited by 346
Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants
Politis, M., Wu, K., Loane, C., Quinn, N. P., Brooks, D. J., Rehncrona, S., Bjorklund, A., Lindvall, O., & Piccini, P. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000976 · Cited by 316
Serotonin in Parkinson's disease
Politis, M., & Niccolini, F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.037 · Cited by 306
The future of stem cell therapies for Parkinson disease
Parmar, M., Grealish, S., & Henchcliffe, C. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0257-7 · Cited by 306
Cell-based therapies for Parkinson disease—past insights and future potential
Barker, R. A., Drouin-Ouellet, J., & Parmar, M. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.123 · Cited by 306
Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease: Two Case Reports
Kefalopoulou, Z., Politis, M., Piccini, P., Mencacci, N., Bhatia, K., Jahanshahi, M., Widner, H., Rehncrona, S., Brundin, P., Björklund, A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4749 · Cited by 300
Self-citationHorstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Cell transplantation in Parkinson's disease: how can we make it work?
Winkler, C., Kirik, D., & Björklund, A. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2004.12.006 · Cited by 255
Piccini, P., Lindvall, O., Bj�rklund, A., Brundin, P., Hagell, P., Ceravolo, R., Oertel, W., Quinn, N., Samuel, M., Rehncrona, S., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200011)48:5<689::aid-ana1>3.0.co;2-n · Cited by 255
Self-citationFactors affecting the clinical outcome after neural transplantation in Parkinson's disease
Piccini, P., Pavese, N., Hagell, P., Reimer, J., Björklund, A., Oertel, W. H., Quinn, N. P., Brooks, D. J., & Lindvall, O. (2005) · Brain · doi:10.1093/brain/awh649 · Cited by 254
Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease
TRANSEURO consortium, & Barker, R. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0507-2 · Cited by 219
Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease
Tabar, V., Sarva, H., Lozano, A. M., Fasano, A., Kalia, S. K., Yu, K. K. H., Brennan, C., Ma, Y., Peng, S., Eidelberg, D., et al. (2025) · Nature · doi:10.1038/s41586-025-08845-y · Cited by 181
Cell Survival and Clinical Outcome Following Intrastriatal Transplantation in Parkinson Disease
Hagell, P., & Brundin, P. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.741 · Cited by 174
Self-citation
Metadata
- Authors
- Brundin, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-07-01
- Volume
- 123
- Issue
- 7
- Pages
- 1380-1390
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2105688544
- Cited by
- 305
- References
- 47
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.